Business
Ligand Enters into OmniAb® Platform License Agreement with Pandion Therapeutics
OmniAb technology to be accessed by Pandion for range of discovery programs SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
About this update from Ligand Pharmaceuticals Incorporated
[{"type":"text","content":"\nOmniAb technology to be accessed by Pandion for range of discovery programs\n\n SAN DIEGO--(BUSINESS WIRE)--\nLigand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide OmniAb license agreement with Pandion Therapeutics. Under the agreement, Pandion will be able to use Ligand’s full OmniAb antibody discovery platform which includes OmniRat®, OmniFlic®, OmniMouse®, OmniChicken® and OmniClic™. OmniAb is licensed to over 40 corporate partners globally, and this deal with Pandion adds to a growing portfolio of OmniAb discovery and clinical development programs. Pandion will pay Ligand an up-front platform access fee, development and regulatory milestone payments, and potential royalties on sales of marketed products.\n\n\n“This agreement provides Pandion access to the industry’s only human immunoglobulin transgenic rats and chickens for efficient generation of mono- and bispecific antibody therapeutics,” said John Higgins, Chief Executive Officer of Ligand. “We are pleased to collaborate with a company committed to novel antibody therapeutics for autoimmune disease and add the OmniAb platform to Pandion’s antibody development capabilities.”\n\n\nAbout Pandion Therapeutics\n\n\nPandion Therapeutics is developing modular biologics for autoimmune regulation that are designed to achieve lasting therapeutic outcomes for patients with autoimmune and inflammatory diseases. Pandion’s approach to developing modular proteins, antibodies and bispecifics includes two key elements: first, the innovative biologics are based on cutting-edge immunomodulators that work systemically by activating regulatory pathways of the immune system that suppress uncontrolled autoimmune responses; and second, these immunomodulators can be combined with tissue-selective tethers, building modular proteins and antibodies that target the precise location within the organ to deliver the desired effect. Pandion is backed by leading life sciences investors including Polaris Partners, Versant Ventures, Roche Venture Fund, SR One, BioInnovation Capital and the JDRF T1D Fund. The company is headquartered in Cambridge, Massachusetts. Please visit www.pandiontx.com.\n\n\nAbout OmniAb®\n\n\nOmniAb is a three-species transgenic-animal platform consisting of five different technologies used for producing mono- and bispecific human therapeutic...